Disruptive Pharma sells GTX platform, retains future royalty and milestone rights
Disruptive Pharma AB (publ) has agreed to sell the GTX platform to a wholly owned subsidiary of Aurelia Invest AB while retaining rights to future...
This website uses cookies to improve your experience. We assume you agree, but you can opt out if you wish. Accept More Info